Phase IV, a Clinical Trial to Assess Safety and Convenience of the Change From DTG/3TC to BIC/FTC/TAF in People With HIV, Good Virological Control and Neuropsychiatric Vulnerabilities

Fundacion SEIMC-GESIDA84 enrolled

Overview

In people infected with HIV, with suppressed HIV viral load and receiving treatment with DTG/3TC: The change to BIC/FTC/TAF will decrease the development of adverse events of neuropsychiatric etiology. The change to BIC/FTC/TAF may improve the patient´s tolerability and degree of acceptance and use of TAR.

The clinical trial is designed to compare people with HIV and neuropsychiatric vulnerabilities, the safety and tolerability of switch to BIC/FTC/TAF versus continue on DTG/3TC. The study includes the inclusion of 80 participants with HIV and who present among their personal history any of those established among the selection criteria (insomnia, anxiety or depression), agree to participate in the same The participants, after signing the informed consent and verifying the meeting of the selection criteria, they will be randomized to continue for 48 weeks with DTG/3TC + BIC/FTC/TAF placebo (arm 1) or switch to BIC/FTC/TAF + placebo DTG/3TC (arm 2). All participants, except those who discontinue the study early, must to complete the same schedule of visits. It will be cause of early discontinuation loss to follow-up, withdrawal of consent, or development of any condition that requires discontinuation or change of assigned treatment. During follow-up, the management of the basic neuropsychiatric pathology of each participant will be performed in accordance with normal clinical practice. In no case, the beginning, the change or the cessation of any pharmacological treatment or neuropsychiatric intervention should be affected by their participation in the study. If the situation arises where any participant developed a severe neuropsychiatric adverse effect (grade 3-4), two specialists in psychiatry experts in the management of patients with HIV would be responsible for evaluating them through the review of their medical history and an interview with the participant in person or via telematics. This evaluation will aim to confirm the relevance of the continuity of the patient in the study and the need for further preferential evaluation by psychiatry.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

HIV Infections

Interventions

BIKTARVY 50Mg-200Mg-25Mg Tablet and Dovato placeboDRUG

The patients randomized to experimental arm will be randomized to Biktarvy + Dovato placebo

Dovato 50Mg-300Mg Tablet + Biktarvy placeboDRUG

The patients randomized to comparador arm will be randomized to Dovato + Biktarvy placebo

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult \>18 years diagnosed with HIV by standard microbiological techniques * Active antiretroviral treatment with DTG/3TC * Last HIV viral load performed on the participant in the 6 months prior to the visit screening \< 50 copies/mL. If the participant does not have an HIV viral load \<50 cop/mL performed in the 14 days prior to the screening visit, it will be necessary to confirm at screening visit that the participant's HIV viral load is \<50 cop/mL * Prior clinical diagnosis, carried out by a qualified specialist physician, of any of the following pathologies: Insomnia Anxiety disorders Depressive disorders Exclusion Criteria: * Allergy or intolerance to any of the components of BIC/FTC/TAF * History of active CNS infections * Active psychosis or suicidal ideation * Pregnant or lactating women, as well as women of childbearing age who do not commit to use at least two contraceptive methods * Any clinical or laboratory condition that in the opinion of the investigator will prevent the participant to complete the study procedures * Participant included in the neuroimaging substudy: Claustrophobia or presence of magnetizable body devices

Locations (14)

H. Universitario Son Espases

Palma de Mallorca, Balearic Islands, Spain

CHUAC

A Coruña, Spain

Hospital de Bellvitge

Barcelona, Spain

Outcomes

Primary Outcomes

The safety of switching to BIC/FTC/TAF versus continuing treatment with DTG/3TC.

Primary endpoint: Proportion of neuropsychiatric adverse effects grade 2-4 (defined using the AIDS Clinical Trials Group Adverse Events Grading Score11) Secondary endpoints: 1. Proportion of grade 2-4 adverse effects (defined using the AIDS Clinical Trials Group Adverse Events Grading Score11) 2. Proportion of ART discontinuations due to neuropsychiatric adverse effects. 3. Proportion of ART discontinuations for any reason.

Time frame: 24-48 weeks

Secondary Outcomes

The desirability of switching to BIC/FTC/TAF versus continuing treatment with DTG/3TC.

Primary endpoint: Changes in sleep quality estimated using the Pittsburgh Sleep Quality Questionnaire (PSQI) Secondary endpoints: 1. Changes in mood estimated using the hospital scale of anxiety and depression (HADS) 2. Changes in the scale of satisfaction with ART (ESTAR) 3. Changes in the Spanish version of the MOS HIV quality of life questionnaire.

Time frame: 24-48 weeks

The efficacy of switching to BIC/FTC/TAF versus continuing treatment with DTG/3TC.

Primary endpoint: Percentage of participants with HIV viral load \>50 copies/mL, according to the Snapshot algorithm of the "US Food and Drug Administration" (margin to demonstrate non-inferiority: 4%) Secondary edpoints: * 1)Proportion of participants with HIV viral load \<50 copies/mL 2\) Proportion of participants with undetectable viral load. 3\) Proportion of patients with failure confirmed virology 4\) Percentage of patients with virological failure 5\) Proportion of participants experiencing blips during the study

Time frame: 24-48 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.